Last updated on April 2019

Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients

Brief description of study

This is a randomized, double-blind, placebo-controlled, multicentre, parallel-group study to assess the cognitive effects of lurasidone in bipolar I and II patients (manic depression) who are in remission from an episode. Participants who show cognitive impairment at the screening visit will be enrolled into the study and randomized at the baseline visit to receive either lurasidone or placebo adjunctive therapy in a 1:1 ratio for 6 weeks.

Clinical Study Identifier: NCT02731612

Find a site near you

Start Over